Drug-induced liver injury (DILI) poses a serious health risk to affected patients and is one of the leading causes of market withdrawal in the pharmaceutical industry. Identification of hepatotoxic compounds in the preclinical phase of drug development is key to preventing DILI. In this poster by Dr. Kristin M. Bricsak, presented at the SOT annual meeting 2021, a functional 3D in vitro model of the human liver is described in detail. The OrganoPlate® LiverTox is compatible with automated liquid handling and validated for hepatotoxicity screening. To build the model, up to 96 independent 3D perfused cultures were established on MIMETAS’ OrganoPlate® 2-lane using automated liquid handling to seed cells, dose, collect media and add assay reagents. This poster shows that the OrganoPlate® LiverTox is a promising platform for hepatotoxicity detection and has the potential to be used for high throughput screening.
- Sign up for our Webinar April 6th: Toxicity testing in a high-throughput organ-on-a-chip platform
- Publication : A 3D microfluidic liver model for high throughput compound toxicity screening in the OrganoPlate®
- OrganoPlate® 2-lane 96